secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2023-02-15T23:59:59+00:00
Accession:  0001770787-23-000006
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics Q4 revenue up 9% to $156.2M; FY net loss triples to $166M, guides FY23 rev $580-600M
--------------------------------------------------------------------------------

- Q4 2022 revenue $156.2M (+9% YoY); FY 2022 revenue $516.4M (+5% YoY).
- Gross margin fell to 76% in Q4 (from 81%) and 77% for FY (from 85%) due to product mix.
- Operating loss widened to $23.1M in Q4 and $167.9M for FY, driven by higher stock-based compensation.
- Net loss for FY 2022 was $166.0M vs $58.2M in 2021; cash + securities $430M.
- FY 2023 revenue guidance $580M-$600M (12-16% growth); began shipping Xenium in situ platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078723000006/0001770787-23-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078723000006/txg-20230215.htm
  HTML page:      https://secwatch.observer/filing/0001770787-23-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer